Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanfeng Tongqiao Diwan is a Traditional Chinese Medicine (TCM) formulation delivered as a dropping pill (diwan). It is primarily investigated for the treatment of Upper Airway Cough Syndrome (UACS), a condition characterized by chronic cough associated with abnormalities in the upper respiratory tract, such as post-nasal drip syndrome. The formulation is designed to "dispel wind" and "open the orifices," which are common therapeutic principles in TCM for respiratory and nasal conditions. Clinical research, including trials sponsored by The First Affiliated Hospital of Guangzhou Medical University, focuses on evaluating its efficacy in reducing cough symptoms and improving airway clearance by addressing underlying inflammation and irritation in the upper airways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanfeng Tongqiao Diwan.